Brought to you by 
Pfizer buying Coley for $164mm
Nov 2007
Executive Summary
Following two years of collaboration, Pfizer is stepping up its relationship with Coley Pharmaceuticals by purchasing the public vaccine adjuvant and immunotherapeutics developer for $8 per share, or a total of about $213mm ($165mm after subtracting Coley's net cash balance). The per share price represents a 154% premium over Coley's preannouncement market average.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer buying Coley for $164mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice